Articles

Optibrium and AstraZeneca sign agreement for global license of StarDrop

Optibrium, a developer of software for drug discovery, today announced that AstraZeneca has signed an agreement to license Optibrium’s StarDrop software.
| 1 min read

Optibrium Ltd.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Mapping cancer signaling at single cell resolution
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Application Note
10x Genomics Logo
Illustration of an antibody intertwined with a DNA double helix.
Mapping immune disease variants at genome scale
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Webinars
BD Bio
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
From absorption to metabolism: predicting human oral drug exposure
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.
Webinars
CN Bio Logo